These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 27880943)

  • 1. TP53 mutations, expression and interaction networks in human cancers.
    Wang X; Sun Q
    Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
    Li VD; Li KH; Li JT
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of
    Hou Y; Tan S; Wang G
    Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranking novel cancer driving synthetic lethal gene pairs using TCGA data.
    Ye H; Zhang X; Chen Y; Liu Q; Wei J
    Oncotarget; 2016 Aug; 7(34):55352-55367. PubMed ID: 27438146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
    Li L; Li M; Wang X
    DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating mutation and gene expression cross-sectional data to infer cancer progression.
    Fleck JL; Pavel AB; Cassandras CG
    BMC Syst Biol; 2016 Jan; 10():12. PubMed ID: 26810975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting clinical outcomes of cancer patients with a p53 deficiency gene signature.
    Schaafsma E; Takacs EM; Kaur S; Cheng C; Kurokawa M
    Sci Rep; 2022 Jan; 12(1):1317. PubMed ID: 35079034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.
    Srihari S; Singla J; Wong L; Ragan MA
    Biol Direct; 2015 Oct; 10():57. PubMed ID: 26427375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Inspection of the Clinical Relevance of TP53 Missense Mutations in Gastric Cancer.
    Moon S; Balch C; Park S; Lee J; Sung J; Nam S
    IEEE/ACM Trans Comput Biol Bioinform; 2019; 16(5):1693-1701. PubMed ID: 29994072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing genomic differences of human cancer stratified by the TP53 mutation status.
    Wang M; Yang C; Zhang X; Li X
    Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
    Kashofer K; Regauer S
    Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
    Neskey DM; Osman AA; Ow TJ; Katsonis P; McDonald T; Hicks SC; Hsu TK; Pickering CR; Ward A; Patel A; Yordy JS; Skinner HD; Giri U; Sano D; Story MD; Beadle BM; El-Naggar AK; Kies MS; William WN; Caulin C; Frederick M; Kimmel M; Myers JN; Lichtarge O
    Cancer Res; 2015 Apr; 75(7):1527-36. PubMed ID: 25634208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosis.
    Tiong KL; Chang KC; Yeh KT; Liu TY; Wu JH; Hsieh PH; Lin SH; Lai WY; Hsu YC; Chen JY; Chang JG; Shieh GS
    Neoplasia; 2014 May; 16(5):441-50. PubMed ID: 24947187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.
    Seagle BL; Eng KH; Dandapani M; Yeh JY; Odunsi K; Shahabi S
    Oncotarget; 2015 Jul; 6(21):18641-52. PubMed ID: 26215675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.